MRNS

Marinus Pharmaceuticals, Inc.

1.34 USD
+0.01 (+0.75%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Marinus Pharmaceuticals, Inc. stock is up 3.08% since 30 days ago. The next earnings date is Aug 8, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 9 June’s closed higher than May. 100% of analysts rate it a buy.

About Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals, Inc. offers ZTALMY, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, tuberous sclerosis complex, depressive disorders, and Lennox-Gestaut Syndrome.

  • Truist Securities
    Tue Jun 18, 13:49
    buy
    confirm
  • HC Wainwright & Co.
    Tue Jun 18, 06:21
    buy
    confirm